The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of the patients we enrolled with unresectable hepatocellular carcinoma and no previous systemic treatment were randomly assigned to receive one of three regimens: tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE), durvalumab (1500 mg every 4 weeks), or sorafenib (400 mg twice daily). The primary objective was overall survival for STRIDE versus sorafenib. Noninferiority for overall survival for durvalumab versus sorafenib was a secondary objective. RESULTS: In total, 1171 patients were randomly assigned to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). The median overall survival was 16.43 months (95% confidence interval [CI], 14.16 to 19.58) with STRIDE, 16.56 months (95% CI, 14.06 to 19.12) with durvalumab, and 13.77 months (95% CI, 12.25 to 16.13) with sorafenib. Overall survival at 36 months was 30.7%, 24.7%, and 20.2%, respectively. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78 (96.02% CI, 0.65 to 0.93; P=0.0035). Overall survival with durvalumab monotherapy was noninferior to sorafenib (hazard ratio, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08). Median progression-free survival was not significantly different among all three groups. Grade 3/4 treatment-emergent adverse events occurred for 50.5% of patients with STRIDE, 37.1% with durvalumab, and 52.4% with sorafenib. CONCLUSIONS: STRIDE significantly improved overall survival versus sorafenib. Durvalumab monotherapy was noninferior to sorafenib for patients with unresectable hepatocellular carcinoma. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03298451.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The response rate was 20% with durvalumab plus tremelimumab and 30% with atezolizumab plus bevacizumab, with median duration of response ranging from 18 months to 22 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-L1 inhibitor-based regimens received approvals in 2020 (atezolizumab plus bevacizumab) and 2022 (tremelimumab plus durvalumab) as first-line treatment options for unresectable hepatocellular carcinoma after showing improved outcomes over sorafenib, with median overall survival ranging from 16 months to 19 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the introduction of PD-L1 inhibitors in this setting, survival benefits versus sorafenib were improved with a median overall survival of 19•2 months with atezolizumab plus bevacizumab, 9,10 16•6 months with durvalumab monotherapy, and 16•4 months with tremelimumab plus durvalumab, 7,8 leading to regulatory”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At the RP2D, the safety profile was consistent with the known safety profile of durvalumab in combination with tremelimumab in adult patients (13, 14), and no new safety signals were identified in our pediatric population.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“durvalumab plus tremelimumab has demonstrated improved OS compared with sorafenib alone in adults with unresectable hepatocellular cancer (14).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“In HIMALAYA, durvalumab plus tremelimumab yielded an objective response rate of 20% and median duration of response of 22•3 months.7”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
Fulgenzi, C. A. M., Scheiner, B., Korolewicz, J., Stikas, C., Gennari, A., Vincenzi, B., Openshaw, M. R., Silletta, M., Pinter, M., Cortellini, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100702 · Cited by 54
Lax, B. M., Palmeri, J. R., Lutz, E. A., Sheen, A. M., Stinson, J. A., Duhamel, L., Santollani, L., Kennedy, A., Rothschilds, A. M., Spranger, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300895120 · Cited by 54
“In October 2022, it was approved in combination with durvalumab (anti- PD-L1) for unresectable hepatocellular carcinoma.”
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
Singal, A. G., Salem, R., Pinato, D. J., & Pillai, A. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.047 · Cited by 56
Allaire, M., & Thabut, D. (2023) · Hepatology · doi:10.1097/hep.0000000000000291 · Cited by 53
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 52
“The Himalaya trial also showed a significantly better OS (16.4 months) with the combination of tremelimumab and durvalumab in comparison to sorafenib (13.8 months) [10].”
InfluentialWatanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53
Allaire, M., Bruix, J., Korenjak, M., Manes, S., Maravic, Z., Reeves, H. L., Salem, R., Sangro, B., & Sherman, M. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100578 · Cited by 52
Self-citationImmunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Lo, J. H.-J., Agarwal, R., Goff, L. W., & Heumann, T. R. (2023) · Cancers · doi:10.3390/cancers15133312 · Cited by 52
Locoregional Therapies for Hepatocellular Carcinoma
Patel, K. R., Menon, H., Patel, R. R., Huang, E. P., Verma, V., & Escorcia, F. E. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47995 · Cited by 59
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 66
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
Bicer, F., Kure, C., Özlük, A. A., El‐Rayes, B. F., & Akce, M. (2023) · Current Oncology · doi:10.3390/curroncol30110711 · Cited by 54
Sangro, B., Galle, P. R., Kelley, R. K., Charoentum, C., Toni, E. N. D., Ostapenko, Y., Heo, J., Cheng, A., Woods, A. W., Gupta, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01462 · Cited by 51
“9 Even when treatment improves survival, this bene fi t can be counter-balanced by the burdenof treatment and/or itspotentialeffect on HRQoL.”
BackgroundResultInfluentialSelf-citationOura, K., Morishita, A., Hamaya, S., Fujita, K., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032805 · Cited by 51
Lorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 53
Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma
Liu, K., Dennis, C. V., Prince, D. S., Marsh‐Wakefield, F., Santhakumar, C., Gamble, J. R., Strasser, S. I., & McCaughan, G. W. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100792 · Cited by 48
Precision surgery for hepatocellular carcinoma
Magyar, C. T. J., Rajendran, L., Li, Z., Banz, V. M., Vogel, A., O'Kane, G. M., Chan, A. C. Y., & Sapisochín, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00434-5 · Cited by 49
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
Vogel, A., Grant, R. C., Meyer, T., Sapisochín, G., O'Kane, G. M., & Saborowski, A. L. (2023) · Hepatology · doi:10.1097/hep.0000000000000726 · Cited by 53
Merle, P., Kudo, M., Edeline, J., Bouattour, M., Cheng, A., Chan, S. L., Yau, T. W. C., Marcelo Garrido, S., Knox, J. J., Daniele, B., et al. (2023) · Liver Cancer · doi:10.1159/000529636 · Cited by 46
“Systemic treatment options in the fi rst-line setting for patients with advanced stage HCC have evolved rapidly, and options now include sorafenib [3], lenvatinib [4], atezolizumab plus bevacizumab [5, 6], and durvalumab plus tremelimumab [7].”
BackgroundSelf-citationHatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023) · Cancers · doi:10.3390/cancers15061798 · Cited by 47
Ikeda, M., Yamashita, T., Ogasawara, S., Kudo, M., Inaba, Y., Morimoto, M., Tsuchiya, K., Shimizu, S., Kojima, Y., Hiraoka, A., et al. (2023) · Liver Cancer · doi:10.1159/000531820 · Cited by 46
“However, Atezo+Bev [5] and Durva+Treme [6] have been demonstrated to yield signi fi cant survival bene fi t over sorafenib in advanced HCC patients.”
BackgroundSelf-citationImmune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 51
“25 HIMALAYA established the superiority over sorafenib of durvalumab (anti- PD-L1) with a single high dose of tremelimumab (anti- CTLA-4) in terms of OS (16.6 months vs 13.8 months) but not in terms of PFS. Similarly, in CheckMate9DW, the combination of nivolumab and ipilimumab (anti- CTLA-4) was…”
InfluentialRoessler, D., Öcal, O., Philipp, A. B., Markwardt, D., Munker, S., Mayerle, J. V., Jochheim, L. S., Hammer, K., Lange, C. M., Geier, A., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04206-8 · Cited by 47
MAFLD: an optimal framework for understanding liver cancer phenotypes
Crane, H., Gofton, C., Sharma, A., & George, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02021-7 · Cited by 46
Lau, G. K. K., Abou‐Alfa, G. K., Cheng, A., Sukeepaisarnjaroen, W., Dao, T. V., Kang, Y., Thungappa, S. C., Kudo, M., Sangro, B., Kelley, R. K., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.017 · Cited by 45
Self-citationLi, Z., Liu, J., Zhang, B., Yue, J., Shi, X., Cui, K., Liu, Z., Chang, Z., Sun, Z., Li, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47420-3 · Cited by 48
“The results from Himalaya trial 10 and IMbrave 150 trial 11 fi rmly established the pivotal roles of immune checkpoint inhibitors (ICIs) in the systemic treatment of HCC. Neoadjuvant therapy strategies incorporating anti-PD-(L)1 antibodies, alone or in combination, have shown encouraging…”
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46
“Frontiers in Immunology 05 Phase III clinical trial HIMALAYA (NCT03298451) were also announced, demonstrating significantly improved ORR and three-year OS rates compared to sorafenib (38).”
BackgroundKumar, A., Acharya, S. K., Singh, S. P., Duseja, A. K., Madan, K., Shukla, A., Arora, A., Anand, A. C., Bahl, A., Soin, A. S., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.08.005 · Cited by 43
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Daher, D., Dahan, K. S. E., & Singal, A. G. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2022.12.30 · Cited by 45
“92).(124) Of interest, the HIMALAYA trial also provided results from landmark analysis at 3 years, demonstrating 30.”
BackgroundResultGiraud, J., Chalopin, D., Ramel, E., Boyer, T., Zouine, A., Derieppe, M., Larmonier, N., Adotévi, O., Bail, B. L., Blanc, J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113773 · Cited by 45
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 45
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49
Sim, Y. K., Chong, M. C., Gandhi, M., Pokharkar, Y. M., Zhu, Y., Shi, L., Li, L., Chen, C., Kudo, M., Lee, J. H., et al. (2023) · Liver Cancer · doi:10.1159/000534513 · Cited by 41
“More recently, positive phase III trials have been reported for new immunotherapeutic drugs as fi rst-line treatment for advanced HCC, such as the combination of atezolizumab plus bevacizumab in 2021 and tremelimumab plus durvalumab in 2022 [10 – 12].”
BackgroundSelf-citationComplete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma
Chiang, C., Chan, S.-K., Chiu, K. W.-H., Lee, F. A. S., Chen, W., Wong, N. S. M., Ho, R. L. M., Lee, V. W. Y., Man, K., Kong, F., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4085 · Cited by 43
Self-citationScheiner, B., Kang, B., Balcar, L., Radu, I.-P., Reiter, F. P., Adžić, G., Guo, J., Gao, X., Yuan, X., Cheng, L., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001163 · Cited by 42
“[3,4,15] Patients with complete response had 1-and 3-year OS rates of 98% and 86%, and 1-and 3-year RFS rates of 76% and 48%, respectively.”
Self-citationTriantafyllou, E., Gudd, C. L. C., & Possamai, L. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01019-7 · Cited by 49
“Combination therapies, including ipilimumab plus nivolumab and durvalumab plus tremelimumab, have demonstrated higher response rates and better clinical outcomes than monotherapies in certain tumour types 36–38 .”
Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma
Caldéraro, J., Tommaso, L. D., Maillé, P., Bèaufrere, A., Nguyễn, C. T., Heij, L. R., Gnemmi, V., Graham, R. P., Charlotte, F., Chartier, S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.019 · Cited by 40
“HCC unfortunately presents few therapeutic options that include the atezolizumab-bevacizumab or durvalumab-tremelimumab combinations.(6,7) Molecular profiling of iCCA has shown that a significant subset of tumors harbor actionable alterations, such as FGFR2 rearrangements and IDH1, BRAF or BRCA mutations.”
BackgroundQin, S., Gu, S., Chan, S. L., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00543-1 · Cited by 45
Self-citationCoffin, P., & He, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713274 · Cited by 23
Finn, R. S., Galle, P. R., Ducreux, M. P., Cheng, A., Reilly, N. R., Nicholas, A., Hernandez, S., Ma, N., Merle, P., Salem, R., et al. (2024) · Liver Cancer · doi:10.1159/000539897 · Cited by 42
Self-citationAdvances in Immunotherapy in Hepatocellular Carcinoma
Bloom, M., Podder, S., Dang, H. T., & Lin, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051936 · Cited by 38
“In the HIMALAYA trial, sub-group analyses suggested greater OS benefit in patients with HBV compared with HCV; however, patients with non-viral etiology still demonstrated survival gain [5].”
InfluentialCurrent Trends in Surgical Management of Hepatocellular Carcinoma
Angeli‐Pahim, I., Chambers, A., Duarte, S., & Zarrinpar, A. (2023) · Cancers · doi:10.3390/cancers15225378 · Cited by 40
“Combination therapy durvalumab, IgG1 κ mAb for PD-L1, and tremelimumab, anti-CTLA-4 mAb, as a first-line therapy significantly improved OS compared to sorafenib for patients with unresectable HCC [25].”
BackgroundTremelimumab and Durvalumab in the Treatment of Unresectable, Advanced Hepatocellular Carcinoma
Castria, T. B. D., Khalil, D. N., Harding, J. J., O'Reilly, E. M., & Abou‐Alfa, G. K. (2022) · Future Oncology · doi:10.2217/fon-2022-0652 · Cited by 36
Self-citationHajra, I. E., Sanduzzi‐Zamparelli, M., Sapena, V., Muñoz, S., Mauro, E., Llarch, N., Iserte, G., Forner, A., Ríos, J., Bruix, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000030 · Cited by 36
“[6] Similarly, durvalumab in monotherapy[5] and tislelizumab[7] are noninferior to sorafenib in first-line, ipilimumab in combination with nivolumab[8,9] as well as pembrolizumab were granted accelerated approval by the Food and Drug Administration[10] and the latter recently showed improved OS in comparison to placeb…”
BackgroundCabibbo, G., Celsa, C., Battaglia, S., Enea, M., Maria, G. D., Grova, A., Ciccia, R., Manfredi, G. F., Iavarone, M. A., Vogel, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2582 · Cited by 36
Xu, D., Wang, H., Bao, Q., Jin, K., Liu, M., Liu, W., Yan, X., Wang, L., Zhang, Y., Wang, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56537-y · Cited by 40
“In recent years, with the advances of immunotherapy, many patients can achieve tumor regression and reduced adverse oncological factors, thereby prolonging survival to the greatest extent and even gaining opportunities for surgery 9,10,14 .”
InfluentialSalvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Alden, S. L., Lim, M., Kao, C., Shu, D. H., Singal, A. G., Noonan, A. M., Griffith, P., Baretti, M., Ho, W. J., Kamel, I. R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0072 · Cited by 35
“In addition, objective responses with ipilimumab plus nivolumab were achieved in patients with primary resistance to anti-PD-(L)1 therapy, adding to growing preclinical and clinical evidence that combined PD-(L)1/CTLA-4 blockade can overcome PD-(L)1 resistance in HCC and other tumor types (10, 13).”
BackgroundResultInfluentialCerreto, M., Cardone, F., Cerrito, L., Stella, L., Santopaolo, F., Pallozzi, M., Gasbarrini, A., & Ponziani, F. R. (2023) · Current Oncology · doi:10.3390/curroncol30100633 · Cited by 41
“These findings support the use of the STRIDE regimen as a possible treatment option in patients with advanced HCC, regardless of baseline ALBI grade [84].”
ResultJi, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 34
Self-citationHsiehchen, D., Beg, M. S., Kainthla, R., Lohrey, J., Kazmi, S. M. A., Khosama, L., Maxwell, M. C., Kline, H., Katz, C., Hassan, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46542-y · Cited by 34
Su, C., Teng, W., Shen, E. Y.-L., Huang, B., Lin, P., Hou, M., Wu, T., Tsan, D., Hsieh, C., Wang, C., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae048 · Cited by 34
“16,17 The exploratory IMbrave 150 report suggested that atezo-bev may provide a survival benefit for high-risk patients.”
BackgroundSystemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Girardi, D. M., Sousa, L. P., Miranda, T. A., Haum, F. N. C., Pereira, G. C. D. B., & Pereira, A. A. L. (2023) · Cancers · doi:10.3390/cancers15061680 · Cited by 35
MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options
Leyh, C., Coombes, J. D., Schmidt, H., Canbay, A. E., Manka, P. P., & Best, J. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040370 · Cited by 38
“In addition to combination therapy, durvalumab was also tested as a monotherapy and was found to be non-inferior to sorafenib [77].”
BackgroundZhu, H.-D., Liu, R., Jia, Z., Xia, D., Zhong, B., Fan, W., Lü, J., Zhao, M. D., & Teng, G. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100037 · Cited by 34
Oura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J., & Kobara, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413590 · Cited by 35
“…has progressed as a systemic therapy for unresectable HCC. Atezolizumab plus bevacizumab (atezo/bev) [14] or durvalumab plus tremelimumab therapy [15], which are regimens including ICIs, has been suggested as the first-line treatments for unresectable HCC. Specifically, atezo/bev therapy, which…”
Kim, B. H., Park, H. C., Kim, T. H., Koh, Y. H., Hong, J. Y., Cho, Y., Sinn, D. H., Park, B., & Park, J. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100991 · Cited by 32
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000530079 · Cited by 32
Self-citationBudhu, A., Pehrsson, E. C., He, A. R., Goyal, L., Kelley, R. K., Dang, H. T., Xie, C., Monge, C., Tandon, M., Ma, L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101052 · Cited by 33
Self-citationContemporary applications of Y90 for the treatment of hepatocellular carcinoma
Yu, Q., Khanjyan, M. V., Fidelman, N. A., & Pillai, A. A. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000288 · Cited by 32
“[57] Recently published phase 1/2a trial using combined TARE and durvalumab included 24 patients with BCLC stage B and C HCC without extrahepatic metastases, noting a median TTP of 15.2 months, median progression-free survival 6.9 months, and 18-month OS of 58.3% (95% CI: 36.4% – 75.0”
InfluentialSong, X., Kelley, R. K., Khan, A. A., Standifer, N. E., Zhou, D., Lim, K., Krishna, R., Liu, L., Wang, K., Mccoon, P. E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1983 · Cited by 31
“Taken together, these findings support the hypothesis that the STRIDE regimen induces a substantial and relevant immune response in patients with uHCC that likely contributes to the improved patient outcomes observed with this regimen without the safety issues typically observed with higher or more frequent doses of t…”
MethodResultInfluentialSelf-citationMunson, P. V., Adamik, J., Hartmann, F. J., Favaro, P. M. B., Ho, D., Bendall, S. C., Combes, A. J., Krummel, M. F., Zhang, K., Kelley, R. K., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3551 · Cited by 34
“…also shown striking improvements in rates of objective radiographic response compared with historical controls (10, 14, 15), and the combination of the PD-L1 inhibitor, durvalumab, with the CTLA4 inhibitor, tremelimumab, improved OS compared with sorafenib in a randomized, phase III trial (8, 16).”
Self-citationGalle, P. R., Finn, R. S., Mitchell, C., Ndirangu, K., Ramji, Z., Redhead, G., & Pinato, D. J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008266 · Cited by 31
Self-citationRecent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
Sadagopan, N., & He, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021259 · Cited by 33
Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 34
Teng, W., Wang, H., Lin, S., & On behalf of Diagnosis Group and Systemic Therapy Group of TLCA (2024) · Liver Cancer · doi:10.1159/000537686 · Cited by 36
“Recently, data from the phase 3 HIMALAYA trial [101] revealed that a single priming dose of trem-elimumab (anti-cytotoxic T lymphocyte-associated antigen 4) added to durvalumab (anti-programmed cell death ligand-1) (STRIDE) provided a statistically signi fi cant survival bene fi t compared to…”
BackgroundShi, Y., Taherifard, E., Saeed, A., & Saeed, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060356 · Cited by 33
“…the results of the phase III HIMALAYA trial demonstrated that both the durvalumab monotherapy and its combination with tremelimumab, when compared to sorafenib, were associated with significantly longer OS in patients with non-viral etiologies, similar to the overall patient population [88].”
ResultPapadakos, S. P., Ferraro, D., Carbone, G., Frampton, A. E., Vennarecci, G., Kykalos, S., Schizas, D., Theocharis, S. E., & Machairas, N. (2023) · Cancers · doi:10.3390/cancers15123161 · Cited by 31
Balcar, L., Scheiner, B., Fulgenzi, C. A. M., D’Alessio, A., Pomej, K., Roig, M. B., Meyer, E. L., Che, J., Nishida, N., Lee, P., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100982 · Cited by 30
“26 These tested the following treatments for advanced HCC, respectively: A+B vs. sorafenib, D+T or dur-valumab monotherapy vs. sorafenib, pembrolizumab vs. placebo, pembrolizumab plus lenvatinib vs. lenvatinib plus placebo, and tislelizumab vs. sorafenib.”
BackgroundInfluentialSelf-citationThe current landscape of therapies for hepatocellular carcinoma
Coffman, K., Xie, C., Hrones, D. M., Ghabra, S., Greten, T. F., & Monge, C. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad052 · Cited by 31
Neoadjuvant systemic therapy for hepatocellular carcinoma
Chick, R. C., Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355812 · Cited by 28
“Additionally, the HIMALAYA trial demonstrated the ef fi cacy of tremelimumab and durvalumab for patients with advanced HCC; in turn, this combination has also been approved as fi rst-line therapy (12).”
Pinato, D. J., D’Alessio, A., Fulgenzi, C. A. M., Schlaak, A. E., Celsa, C., Killmer, S., Blanco, J. M., Ward, C. E., Stikas, C., Openshaw, M. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0177 · Cited by 29
Rauth, S., Malafa, M. P., Ponnusamy, M. P., & Batra, S. K. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.005 · Cited by 29
Badhrinarayanan, S., Cotter, C., Zhu, H., Lin, Y., Kudo, M., & Li, D. (2024) · Future Oncology · doi:10.1080/14796694.2024.2355863 · Cited by 32
Self-citationAfra, F., Mahboobipour, A. A., Farid, A. S., & Ala, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115104 · Cited by 30
Cabibbo, G., Daniele, B., Borzio, M., Gardini, A. C., Cillo, U., Colli, A., Conforti, M., Dadduzio, V., Dionisi, F., Farinati, F., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.10.029 · Cited by 29
Self-citationVillalobos, A., Dabbous, H., Little, O., Gbolahan, O. B., Akce, M., Lilly, M., Bercu, Z. L., & Kokabi, N. (2023) · Current Oncology · doi:10.3390/curroncol30120734 · Cited by 28
“More recently, durvalumab and tremelimumab combination therapy was approved for the front-line therapy of advanced HCC based on the HIMALAYA trial [8].”
BackgroundBiomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, R., Jin, T., & Xu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326097 · Cited by 30
“In the IMbrave150 trial investigating Atez/ Bev in HCC, the median OS of patients treated with this combination therapy was shorter in nonviral-related HCC compared to HBV-and HCV-related HCC (16).”
BackgroundInfluentialGalasso, L., Cerrito, L., Maccauro, V., Termite, F., Mignini, I., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137191 · Cited by 28
“The combination of durvalumab and tremelimumab has already been included as a first-line option in the latest HCC treatment recommendations [143].”
BackgroundRoussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 28
“Unfortunately, according to the RCTs data, only 10–30% of patients with advanced HCC demonstrate an objective response to ICIs (Table 1) and, when the disease control rate (including patients with stable disease) is considered, immunotherapy is effective in only 70% of patients.”
BackgroundResultInfluentialMyojin, Y., McCallen, J., Ma, C., Bauer, K. C., Ruf, B., Benmebarek, M.-R., Green, B. L., Wabitsch, S., McVey, J. C., Fu, C., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100959 · Cited by 27
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Chew, V., Chuang, C.-H., & Hsu, C. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01011-y · Cited by 29
Magyar, C. T. J., O'Kane, G. M., Aceituno, L., Li, Z., Vogel, A., Bruix, J., Mazzaferro, V., & Sapisochín, G. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00857 · Cited by 27
McArthur, H. L., Tolaney, S. M., Dent, R. A., Schmid, P., Asselah, J., Liu, Q., Meisel, J. L., Niikura, N., Park, Y. H., Werutsky, G., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251316176 · Cited by 29
Lin, Z., Wang, W., Yan, Y., Ma, Z., Xiao, Z., & Mao, K. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002322 · Cited by 27
“Particularly, the combination of immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors, antiangiogenic agents, and local therapy, such as TACE and HAIC, has demonstrated an enhanced objective response rate compared to previous modalities [ 14-16 ] .”
Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
Özer, M., Goksu, S. Y., Akagündüz, B., George, A., & Şahin, İ. (2023) · Cancers · doi:10.3390/cancers15061808 · Cited by 27
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma
Villarruel-Melquiades, F., Mendoza‐Garrido, M. E., García-Cuellar, C. M., Sánchez-Pérez, Y., Pérez‐Carreón, J. I., & Camacho, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i17.2571 · Cited by 27
Krishnamurthy, N., Nishizaki, D., Lippman, S. M., Miyashita, H., Nesline, M., Pabla, S., Conroy, J. M., DePietro, P., Kato, S., & Kurzrock, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220510 · Cited by 28
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 28
“A Durvalumab and Tremelimumab (Figure 1) combination therapy has shown clinical benefits against solid tumors such as HNSCC [88] and unresectable hepatocellular carcinoma (uHCC) [89].”
BackgroundWu, S., Anand, N., Guo, Z., Li, M., Figueroa, M. S., Jung, L., Kelly, S., & Franses, J. W. (2025) · Cancers · doi:10.3390/cancers17111860 · Cited by 27
“The HIMALAYA study [124] demonstrated a significant benefit of a single loading dose of tremelimumab combined with durvalumab, with a very durable benefit in a small but significant minority of treated patients [125].”
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 26
Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma
Woo, S. M.-L., Kimchy, A. V., Sequeira, L. M., Dorris, C. S., He, A. R., & Rangnekar, A. S. (2022) · Current Oncology · doi:10.3390/curroncol29120771 · Cited by 26
Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
Pinto, E., Meneghel, P., Farinati, F., Russo, F. P., Pelizzaro, F., & Gambato, M. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.08.062 · Cited by 27
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Becht, R., Kiełbowski, K., & Wasilewicz, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031456 · Cited by 29
Han, J. W., Sohn, W., Choi, G. H., Jang, J. W., Seo, G. H., Kim, B. H., & Choi, J. Y. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.13 · Cited by 25
Spatial single-cell omics: new insights into liver diseases
Suo, Y., Thimme, R., & Bengsch, B. (2025) · Gut · doi:10.1136/gutjnl-2024-332105 · Cited by 29
Cabibbo, G., Celsa, C., Bhoori, S., Reiberger, T., Pinato, D. J., & Cammà, C. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.020 · Cited by 30
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 31
Sinner, F., Pinter, M., Scheiner, B., Ettrich, T. J., Sturm, N., Gonzalez-Carmona, M. A., Waidmann, O., Finkelmeier, F., Himmelsbach, V., Toni, E. N. D., et al. (2022) · Cancers · doi:10.3390/cancers14235966 · Cited by 25
“However, among combination therapies, only the ICI combination with durvalumab and tremelimumab provided a survival benefit over sorafenib [24], whereas both the COSMIC312 and LEAP-002 trials, which investigated the superiority of a combination TKI and ICI compared with TKI monotherapy, provided negative results with…”
BackgroundResult
Metadata
- Authors
- Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., Rimassa, L., Breder, V., Vasilyev, A., Heurgué, A., Tam, V. C., Mody, K., Thungappa, S. C., Ostapenko, Y., Yau, T., Azevedo, S., Varela, M., Cheng, A.-L., Qin, S., Galle, P. R., Ali, S., Marcovitz, M., Makowsky, M., He, P., Kurland, J. F., Negro, A., & Sangro, B.
- Affiliations
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
- Humanity & Health (CN)
- Kindai University Hospital (JP)
- Chinese University of Hong Kong (HK)
- University of California, San Francisco (US)
- Kyorin University (JP)
- Khon Kaen University (TH)
- Asan Medical Center (KR)
- Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam
- Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Humanitas University (IT)
- Russian Cancer Research Center NN Blokhin (RU)
- Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia
- Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France
- University of Calgary (CA)
- Mayo Clinic (US)
- Sri Venkateshwara Hospital, Bangalore, India
- National Cancer Institute (UA)
- Queen Mary Hospital (CN)
- Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias–Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain
- National Taiwan University (TW)
- 81th Hospital of PLA (CN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- AstraZeneca (United States) (US)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- ORCID
- Lau, George
- Kudo, Masatoshi
- Chan, Stephen L.
- Kelley, Robin Kate
- Furuse, Junji
- Sukeepaisarnjaroen, Wattana
- Kang, Yoon-Koo
- Rimassa, Lorenza
- Breder, Valeriy
- Heurgué, Alexandra
- Tam, Vincent C.
- Mody, Kabir
- Yau, Thomas
- Cheng, Ann-Lii
- Qin, Shukui
- Galle, Peter R.
- Marcovitz, Michelle
- He, Philip
- Kurland, John F.
- Negro, Alejandra
- Sangro, Bruno
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-26
- Volume
- 1
- Issue
- 8
- Pages
- EVIDoa2100070-EVIDoa2100070
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4281645619
- Cited by
- 1,576
- References
- 23
- Citations by year
- 2026: 356 · 2025: 450 · 2024: 421 · 2023: 284 · 2022: 63
- FWCI
- 181.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- tremelimumab, durvalumab, hepatocellular carcinoma, unresectable liver cancer, CTLA-4 blockade, PD-L1 blockade, sorafenib, overall survival, non-inferiority, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, treatment-emergent adverse events, immune-related adverse events, non-small cell lung cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Sorafenib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
